share_log

Oncocyte to Participate in "J.P. Morgan Week" and Host Investor Meetings

Oncocyte to Participate in "J.P. Morgan Week" and Host Investor Meetings

Oncocyte将参加“J.P.摩根周”和举办投资者会议
GlobeNewswire ·  12/10 05:05

January 13-16, 2025, San Francisco, CA

2025年1月13日至16日,加利福尼亚州旧金山

IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend "J.P. Morgan Week," coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors.

加利福尼亚州欧文,2024年12月9日(环球新闻通讯社)——oncocyte corp.(纳斯达克:OCX),一家领先的诊断科技公司,今天宣布首席执行官乔希·里格斯和首席财务官安德丽亚·詹姆斯将出席与第43届年度JP摩根医疗会议同时进行的“JP摩根周”,该会议将在2025年1月13日至16日于旧金山举行。在此期间,oncocyte将与感兴趣的投资者进行一对一的会议。

Investors wishing to schedule a meeting are encouraged to contact Julie Silber at PCG Advisory via email at jsilber@pcgadvisory.com.

希望安排会议的投资者可以通过电子邮件联系PCG顾问的朱莉·西尔伯,邮箱是jsilber@pcgadvisory.com。

Event: "J.P. Morgan Week"
Dates: January 13-16, 2025
Location: San Francisco, CA, USA

活动:“JP摩根周”
日期:2025年1月13日至16日
地点:加利福尼亚州旧金山,美国

About Oncocyte
Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft is a clinical blood-based solid organ transplantation monitoring test. GraftAssure is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit . For more information about our products, please visit the following web pages:

关于Oncocyte
Oncocyte是一家诊断技术公司。该公司的检测旨在帮助医生及其患者获得更清晰和更有信心的信息。VitaGraft是一种临床血液基固体器官移植监测测试。GraftAssure是一种仅限研究用途(RUO)的血液基固体器官移植监测测试。DetermaIO是一种基因表达测试,用于评估肿瘤微环境,预测对免疫疗法的反应。DetermaCNI是一种用于监测癌症患者治疗效果的血液基监测工具。有关Oncocyte的更多信息,请访问。有关我们产品的更多信息,请访问以下网页:

VitaGraft Kidney –
VitaGraft Liver –
GraftAssure –
DetermaIO –
DetermaCNI –

VitaGraft 肾脏 –
VitaGraft 肝脏 –
GraftAssure –
DetermaIO –
DetermaCNI –

VitaGraft, GraftAssure, DetermaIO, and DetermaCNI are trademarks of Oncocyte Corporation.

VitaGraft,GraftAssure,DetermaIO和DetermaCNI是Oncocyte公司的商标。

CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com

联系人:
杰夫·拉姆森
PCG 咨询
(646)863-6893
jramson@pcgadvisory.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发